6 April 2020 - - US-based FHI Clinical Inc.  has partnered with Seattle-based not-for-profit organisation Infectious Disease Research Institute to provide full-service contract research organisation capabilities for an immunotherapy clinical trial to combat moderate to severe cases of COVID-19, the company said.

IDRI recently announced it has received funding from New Jersey-based Celularity, a clinical-stage cell therapeutics company, to launch a clinical trial to investigate the use of Celularity's NK cell therapy, currently under study for the treatment of various hematologic cancers and solid tumors, as a potential treatment option against the novel coronavirus.

FHI Clinical is a full-service contract research organization with the global expertise, responsive approaches and proven solutions to manage complex clinical research in resource-limited settings around the world.

Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of global importance.

By integrating capabilities, we strive to enable an efficient pathway to bring scientific innovation from the lab to the people who need it most.